131I-angiostatin 在荷瘤小鼠体内的分布及放射受体显像

本实验研究^131I-angiostatin在荷Lewis肺癌C-57小鼠体内的分布，并进行放射笥受体显像，为临床应用提供依据。Aangiostatin用氯胺-T法行^131I标记后，尾静脉注入荷肺癌C-57小鼠体内，24、48、96、144H后进行放射受体显像，并于48、96、144h分批处死实验小鼠，测定心脏等11种脏器和肿瘤组织的单位重量放射性比值（T/NT），各组织摄取百分数（%ID/g）。结果发现，^131I-angiostatin尾静脉注射后，48h内以全身分布为主，96h后肿瘤部位显像，并呈高度特异性浓集，γ显像结果与体内分结果一致，SPECT图像质量与与T/NT值有关。本研究证实^131I-angiostatin可以待异地与肺癌组织内血管内皮细胞上的受体结合，具有导向肺癌组织的作用。

DISTRIBUTION AND RADIORECEPTORIMAGING OF 131I-LABELED ANGIOSTATIN IN TUMOR-BEARING MICE

To provide an evidence for clinical application, the distribution and radioimmunoimaging of 131I-labeled angiostatin in tumor-bearing mice were studied. Angiostatin was labeled with 131 I by the conventional chloramines T (Ch-T) method and injected into C-57 mice bearing Lewis lung cancer. The biodistribution of 131 I-angiostatin and whole body ECT imaging were studied at various intervals after injection. The average percentage of ID/g was 12. 48, 18. 56 and 23. 17 for tumor and 7. 04 ,5. 47 and 1. 73 for liver at 48, 96, 144 hours postinjection, respectively. The T/NT ratios were 1. 77, 3. 39 and 13. 39 for liver at 48 ,96 and 144 hours postinjection, respectively. The tumor was showed clearly at 96 hours after injection . The quality of tumor imaging was relevant to the T/NT ratio . The results demonstrated that the 131I-angiostatin binds specifically to the receptor on endothelial cells in the tumor and may also possess the capability of locating lung cancer tissue.